期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

靶向急性髓性白血病的酶抑制剂研究进展

Advances in the Research of Enzyme Inhibitors for AML
下载PDF
导出
摘要 急性髓性白血病(AML)是一种恶性克隆性疾病,占白血病患者总数的80%左右。目前,已发现多种用来治疗AML的酶类抑制剂,并取得了一定的成果。本文以AML为主要适应症,主要针对已经上市及处于临床研究阶段的FLT3和IDH小分子抑制剂作一综述。 Acute myeloid leukemia(AML) is a malignant clonal disease, accounting for 80 % of the total number of leukemia patients. Currently, a variety of potent enzyme inhibitors have been found for the treatment of AML. In this paper, we mainly introduce the FLT3 and IDH small molecule inhibitors which have been approved or are in clinical for the treatment of AML.
作者 鲍吉银 张明亮 陆涛 王越 Bao Jiyin;Zhang Mingliang;Lu Tao;Wang Yue(School of Sciences,China Pharmaceutical University,Nanjing 211198,China)
机构地区 中国药科大学理学院
出处 《广东化工》 CAS 2019年第5期116-119,共4页 Guangdong Chemical Industry
关键词 急性髓性白血病 IDH FLT3 acute myeloid leukemia idh flt3
分类号 R979.1 [医药卫生—药品]
  • 相关文献

参考文献1

二级参考文献13

  • 1Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science, 2008; 321 (5897) :1807 - 1812.
  • 2Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med,2009 ;360 ( 8 ) :765 - 773.
  • 3Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med,. 2009 ;361 ( 1 ) :1058 - 1066.
  • 4Schleuk RF, Doher K, Krauter J, et al. Mutations and treatment outcome in cytogenetieaUy normal acute myeloid leukemia. N Engl J Med, 2008; 358(18): 1909 -1918.
  • 5Pabst T, Eyholzec M, Fos J, et al. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. British J Cancer, 2009; 100(8) :1343 -1346.
  • 6Struys EA. D-2-Hydroxyglutaric aciduria: Unravelling the biochemical pathway and the genetic defect. J Inherit Metab Dis, 2006 ;29 ( 1 ) .21 -29.
  • 7Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia (AML) : prevalence and prognostic value.Blood ,2010 ; 116 (12) :2122 - 2126.
  • 8Zou Y, Zeng Y, Zhang DF, et al. IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. Biochemical and Biophysical Research Communications,2010 ;402 (2) :378 - 38.
  • 9Chou WC, Hou HA, Chen CY, et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood, 2010; 115 ( 14 ) : 2749 - 2754.
  • 10Zhao SM, Lin Y, Xu W, et al. Glioma-derived mutations in IDHI dominantly inhibit IDH1 catalytic activity and induce HIF-1a. Science,2009;324(5924) :261 -265.

共引文献5

广东化工
2019年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部